Drug Trial Radar · NCT01080807
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
Last checked: Nov 20, 2026Latest source record: Jun 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Mar 2010
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.
Conditions
- Excessive Sleepiness
Interventions
ArmodafinilDrug
At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Matching PlaceboDrug
At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at EndpointTime frame: Baseline and week 6 (or last observation after baseline)
Locations
63 sites in 1 country. Site status is shown where the registry gives one.
REM Medical Sleep Center
Phoenix, Arizona
REM Medical Clinical Research
Tucson, Arizona
Central Arkansas Research
Hot Springs, Arkansas
Clinical Study Centers LLC
Little Rock, Arkansas
Peninsula Sleep Center
Burlingame, California
Avastra Clinical Trials
Fountain Valley, California
Pacific Sleep Medicine Services Inc
Los Angeles, California
Southwestern Research Inc
Pasadena, California
Pacific Sleep Medicnie Services Inc
Redlands, California
Stanford University Medical Center
Redwood City, California
Dormir Clinical Trials, Inc.
San Diego, California
Southwestern Research Inc
Santa Ana, California
St Johns Medical Plaza Sleep Disorders Center
Santa Monica, California
PAB Clinical Research
Brandon, Florida
MD Clinical
Hallandale, Florida
Compass Research LLC
Orlando, Florida
Broward Research Group
Pembroke Pines, Florida
Miami Research Associates
South Miami, Florida
Florida Sleep Institute
Spring Hill, Florida
Clinical Research Group of St Petersburg
St. Petersburg, Florida
SomnoMedics
Tampa, Florida
Neurotrials Research Inc
Atlanta, Georgia
Sleep Disorders Center of Georgia-Peachtree
Atlanta, Georgia
Sleep Disorders Center of Georgia-Gainesville
Gainesville, Georgia
Sleepmed Inc
Macon, Georgia
Chicago Research Center
Chicago, Illinois
Suburban Lung Associates
Elk Grove Village, Illinois
The Center for Sleep and Wake Disorders d/b/a Midwest Neuro
Danville, Indiana
Fort Wayne Neurological Center
Fort Wayne, Indiana
Rehabilitation Associates of Indiana
Indianapolis, Indiana
Goldpoint Clinical Research
Indianapolis, Indiana
University of Iowa Hospitals
Iowa City, Iowa
Vince and Associates Clinical Research
Overland Park, Kansas
Community Research
Crestview, Kentucky
Kentucky Research Group
Louisville, Kentucky
Helene A. Emsellem, MD
Chevy Chase, Maryland
Sleep Health Center
Brighton, Massachusetts
St Mary's of Michigan
Saginaw, Michigan
The Center for Sleep Medicine
Hattiesburg, Mississippi
Washington University Sleep Medicine Center
St Louis, Missouri
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.